Article, 2024

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Leukemia, ISSN 1476-5551, 0887-6924, Pages 1-9, 10.1038/s41375-024-02341-4

Contributors

Efficace, Fabio 0000-0002-5065-5166 (Corresponding author) [1] Mahon, Francois-Xavi Er [2] Richter, Johan 0000-0002-0374-6823 [3] Piciocchi, Alfonso 0000-0001-8648-885X [1] Cipriani, Marta 0000-0001-6159-8059 [1] [4] Nicolini, Franck Emmanuel [5] Mayer, Jiri [6] Zackova, Daniela 0000-0001-9802-8148 [6] Janssen, Jeroen J W M Jwm 0000-0001-9567-1955 [7] Panayiotidis, Panayiotis P [8] [9] Vestergaard, Hanne Thang 0000-0002-9354-8221 [10] Koskenvesa, Perttu 0000-0002-7121-321X [11] Almeida, A M Antonio Medina 0000-0003-4361-0928 [12] [13] Hjorth-Hansen, Henrik [14] Martinez-Lopez, Joaquin [15] Olsson-Strömberg, Ulla [16] Hochhaus, Andreas 0000-0003-0626-0834 [17] Berger, Marc Gabriel 0000-0003-1858-0587 [18] [19] Etienne, Gabriel [20] [21] Klamová, Hana [22] Faber, Edgar [23] Rousselot, Philippe H 0000-0003-3238-4494 [24] Pfirrmann, Markus 0000-0002-8948-0690 [25] Saussele, Susanne 0000-0003-0357-5785 [26]

Affiliations

  1. [1] Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy
    2. [NORA names: Italy; Europe, EU; OECD];
  2. [2] University of Bordeaux
    3. [NORA names: France; Europe, EU; OECD];
  3. [3] Skåne University Hospital
    4. [NORA names: Sweden; Europe, EU; Nordic; OECD];
  4. [4] Sapienza University of Rome
    5. [NORA names: Italy; Europe, EU; OECD];
  5. [5] Centre Léon Bérard
    6. [NORA names: France; Europe, EU; OECD];

Abstract

Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively. Patients were categorized into the following age groups: 18–39, 40–59, 60–69 and ≥70 years. Of 728 patients evaluated at baseline, 686 (94%) completed HRQoL assessments. The median age at TKI discontinuation was 60 years. Our findings indicate that HRQoL and symptom trajectories may vary depending on specific age groups, with younger patients benefiting the most. Improvements in patients aged 60 years or older were marginal across several HRQoL and symptom domains. At the time of considering TKI discontinuation, physicians could inform younger patients that they may expect valuable HRQoL benefits. Considering the marginal improvements observed in patients aged 60 years or above, it may be important to further investigate the value of TFR compared to a lowest effective dose approach in this older group of patients.

Keywords

EORTC, EORTC QLQ-C30, European countries, FACIT-Fatigue questionnaire, HRQoL, HRQoL assessment, HRQoL benefits, HRQoL results, Limited data, MR4, QLQ-C30, age, age groups, approach, assess HRQoL, assessment, baseline, benefits, chronic myeloid leukemia, chronic myeloid leukemia patients, countries, data, discontinuation, discontinuation of tyrosine kinase inhibitors, domain, dosing approach, fatigue, findings, group, group of patients, health-related quality, health-related quality of life, improvement, inhibitors, kinase inhibitors, leukemia, leukemia patients, life, marginal improvement, median age, myeloid leukemia, myeloid leukemia patients, older group, older group of patients, patients, physicians, quality of life, questionnaire, remission, results, symptom domains, symptom trajectories, symptoms, symptoms of patients, trajectory, treatment-free remission, trials, tyrosine, tyrosine kinase inhibitors, tyrosine kinase inhibitors discontinuation, years, younger patients

Funders

  • National Cancer Institute
  • Ministère des Solidarités et de la Santé
  • European Commission

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+